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ABSTRACT: 
We aimed to elucidate the role of vitamin D supplementation on adipokines through a systematic 
review and a meta-analysis of randomized placebo-controlled trials (RCTs). The search included 
PUBMED, Scopus, Web of Science and Google Scholar through July 1st, 2015. Finally we 
identified 9 RCTs and 484 participants. Meta-analysis of data from 7 studies did not find a 
significant change in plasma adiponectin concentrations following vitamin D supplementation 
(mean difference [MD]: 4.45%, 95%CI: -3.04, 11.93, p=0.244; Q=2.18, I2=0%). In meta-
regression, changes in plasma adiponectin concentrations following vitamin D supplementation 
were found to be independent of treatment duration (slope: 0.25; 95%CI: -0.69, 1.19; p=0.603) 
and changes in serum 25-hydroxy vitamin D [25(OH)D] levels (slope: -0.02; 95%CI: -0.15, 0.12; 
p=0.780). Meta-analysis of data from 6 studies did not find a significant change in plasma leptin 
concentrations following vitamin D supplementation (MD: -4.51%, 95%CI: -25.13, 16.11, 
p=0.668; Q=6.41, IP2 P=21.97%). Sensitivity analysis showed that this effect size is sensitive to one 
of the studies; removing it resulted in a significant reduction in plasma leptin levels (MD: -
12.81%, 95%CI: -24.33, -1.30, p=0.029). In meta-regression, changes in plasma leptin 
concentrations following vitamin D supplementation were found to be independent of treatment 
duration (slope: -1.93; 95%CI: -4.08, 0.23; p=0.080). However, changes in serum 25(OH)D were 
found to be significantly associated with changes in plasma leptin levels following vitamin D 
supplementation (slope: 1.05; 95%CI: 0.08, 2.02; p=0.033). In conclusion, current data did not 
indicate a significant effect of vitamin D supplementation on adiponectin and leptin levels.  
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INTRODUCTION 
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Vitamin D, a fat-soluble vitamin, plays an important role in bone metabolism and calcium 
homeostasis [1]. However it has been increasingly recognized that vitamin D deficiency may play 
a role in several health conditions including cardiovascular disease (CVD) risk. Vitamin D can be 
present in two hormone precursor forms: ergocalciferol (vitamin D2), found in plants and 
cholecalciferol (vitamin D3) found in oily fish or synthesized by the skin from 7-
dehydrocholesterol during exposure to ultraviolet (UV) rays in sunlight [2]. Both D2 and D3 can 
be ingested in the form of supplementation or fortified foods. Ergocalciferol and cholecalciferol 
are then hydroxylated in the liver to form 25-hydroxycholecalciferol (calcidiol or 25(OH)D), 
which is the best biomarker of vitamin D stores and used to determine sufficiency/deficiency 
states.  Calcidiol is transported to the proximal tubules of the kidneys, where it is hydroxylated by 
a 1α-hydroxylase enzyme (gene: CYP27B1) to form calcitriol (1,25-dihydroxycholecalciferol and 
abbreviated to 1,25(OH)2D), the biologically active form of vitamin D [3]; this process is a 
tightly regulated by parathyroid hormone levels and serum calcium and phosphorous levels.  
The biological actions of 1,25(OH)2D) are mediated through the vitamin D receptor (VDR), 
a member of the nuclear receptor superfamily, which are widely expressed throughout human 
tissues: adipocytes, smooth muscles, skin, cells of the immune system, colon, pancreatic β-cells, 
keratinocytes, osteoblasts and the vasculature [4]. Emerging evidence has suggested a link 
between vitamin D deficiency and CVD risk, diabetes mellitus (DM), hypertension and 
dyslipidemia [5]. Lower concentrations of circulating 25(OH)D were associated with higher 
fasting glucose levels, reduced insulin sensitivity, and increased risk of type 2 DM [6]. 
Furthermore, many clinical studies showed that serum 25(OH)D concentrations are inversely 
correlated with body mass index (BMI), fat mass or percentage of body fat and waist 
circumference [4]. Recently, the role of vitamin D in the regulation of adipogenesis and thereby 
in the control of energy homeostasis has become another highly debated issue [7].  
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Adipose tissue secretes bioactive peptides, termed adipokines, including leptin and 
adiponectin, which play an important role in the regulation of energy homeostasis by influencing 
several biological processes, such as food intake, insulin action, lipid, and glucose metabolism, 
regulation of energy balance, coagulation, angiogenesis and vascular remodeling [8]. Altered 
levels of adipokines have been implicated in the pathogenesis of insulin resistance, dyslipidemia 
and atherosclerosis [9]. Adiponectin is a protein hormone that modulates a number of metabolic 
processes, especially carbohydrate and fatty acid metabolism [10]. It has anti-atherosclerotic, as 
well as anti-inflammatory and anti-diabetic properties [11]. According to recent findings, 
hypoadiponectinemia can increase the risk of metabolic syndrome and coronary artery disease 
[12, 13]. Moreover, the secretion of adiponectin decreases with obesity and increases with body 
mass reduction [14]. It has been shown that the reduction of adiponectin concentrations is 
correlated with insulin resistance and hyperinsulinemia [15]. Another adipokine, leptin, acts on 
specific receptors in the hypothalamus to decrease appetite and to increase energy expenditure 
when body fat store is increased. Elevated serum leptin levels signal excessive energy storage to 
the central nervous system to suppress food intake and increase energy consumption [16]. 
Vitamin D supplementation might have different effects on adipokine homeostasis. 
Experimental data suggested that vitamin D supplementation regulates the expression of 
adipokines in visceral fat [17]. Moreover, it has been shown that serum 25(OH)D levels are 
positively correlated with the plasma levels of adiponectin [18]. Some studies reported that 
vitamin D may decrease the plasma levels of leptin, while others demonstrated an increase 
production of leptin after vitamin D supplementation. Thus, the data regarding the effects of 
vitamin D on adipokines are controversial. Therefore, we performed a systematic review of the 
literature and a meta-analysis of randomized placebo-controlled trials to elucidate the impact of 
vitamin D supplementation therapy on plasma adipokines concentrations. 
5 
 
 
METHODS  
Search strategy 
This study was designed according to the guidelines of the 2009 preferred reporting items for 
systematic reviews and meta-analysis (PRISMA) statement [19]. PUBMED, Scopus, Web of 
Science (WoS) and Google Scholar databases were searched using the following search terms in 
titles and abstracts: (vitamin D OR ergocalciferol OR cholecalciferol) AND (leptin) AND/OR 
(adiponectin) AND (randomized controlled trial). The wild-card term ‘‘*’’ was used to increase 
the sensitivity of the search strategy. The search was limited to articles published in English 
language. The literature was searched from inception to July 1st, 2015. The search was limited to 
studies in humans. Selected articles were searched to identify further relevant studies. Two 
reviewers (MD and MCS) evaluated each article separately. Disagreements were resolved by 
agreement and discussion with a third party (MB). 
   
Study Selection 
Original studies were included if they met the following inclusion criteria: (i) being a clinical 
trial with either parallel or cross-over design, (ii) investigating the impact of vitamin D, either as 
monotherapy or combination therapy with calcium, on serum/plasma concentrations of 
adiponectin and/or leptin, and, (iii) presentation of sufficient information on adipokine 
concentrations at baseline and at the end of follow-up in each group or providing the net change 
values.  
Exclusion criteria were: (i) non-interventional studies, (ii) uncontrolled studies, (iii) 
observational studies with case-control, cross-sectional or cohort design, and, (iv) lack of 
sufficient information on baseline or follow-up adipokine concentrations.  
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Data extraction  
Eligible studies were reviewed and the following data were abstracted (MD and MCS): 1) 
first author's name, 2) year of publication, 3) country were the study was performed, 4) study 
design, 5) number of participants in the vitamin D and control groups, 6) intervention assigned to 
the control group, 7) route of administration (single bolus dose or daily dose), 8) type and dose of 
vitamin D, 9) treatment duration, 10) age, gender and body mass index (BMI) of the participants, 
10) baseline and end-trial values for weight and BMI, 11) systolic and diastolic blood pressures, 
and, 12) data regarding baseline and follow-up serum concentrations of 25(OH)D. 
Data extraction was performed independently by 2 reviewers; disagreements were resolved 
by a third reviewer. 
 
Risk of bias assessment 
According to the Cochrane Collaboration [20], a specific tool for assessing risk of bias in 
each involved study comprises judgment of specific features of the study. This involves 
evaluating the risk of bias as ‘low risk’, ‘high risk or ‘unclear risk’. The last category presents 
either lack of information or uncertainty over the potential for bias. There are seven checked 
areas including: sequence generation (selection bias), allocation sequence concealment (selection 
bias), blinding of participants and personnel (performance bias), blinding of outcome assessment 
(detection bias), incomplete outcome data (attrition bias), selective outcome reporting (reporting 
bias) and other potential sources of bias. 
Risk-of-bias assessment was performed independently by 2 reviewers; disagreements were 
resolved by a third reviewer. 
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Quantitative Data Synthesis 
Meta-analyses were conducted using Comprehensive Meta-Analysis (CMA) V2 software 
(Biostat, NJ) [21]. Net changes in measurements (change scores or mean differences [MD]) were 
calculated as follows: measure at end of follow-up − measure at baseline. All values were 
collated as percent change from baseline in each group. Standard deviations (SDs) of the MD 
were calculated using the following formula: SD = square root [(SDpre-treatment)2 + (SDpost-treatment)2 
– (2R × SDpre-treatment × SDpost-treatment)], assuming a correlation coefficient (R) = 0.5. Where 
standard error of the mean (SEM) was only reported, standard deviation (SD) was estimated 
using the following formula: SD = SEM × sqrt (n), where n is the number of subjects. 
Net changes in measurements (change scores) were calculated for parallel trials, as follows: 
(measure at the end of follow-up in the treatment group − measure at baseline in the treatment 
group) − (measure at the end of follow-up in the control group − measure at baseline in the 
control group). A random-effects model and the DerSimonian-Laird method were used to 
compensate for the heterogeneity between studies in terms of study design, treatment duration, 
and the characteristics of populations being studied [22]. Inter-study heterogeneity was assessed 
using Cochran Q test and I2 index. In order to evaluate the influence of each study on the overall 
effect size, sensitivity analysis was conducted using leave-one-out method, i.e. iteratively 
removing one study each time and repeating the analysis. 
 
 
 
 
Meta-regression 
A weighted random-effects meta-regression using unrestricted maximum likelihood model 
was performed to assess the association between the overall estimate of effect size with potential 
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moderator variables including duration of supplementation, baseline serum 25(OH)D and 
changes in serum 25(OH)D concentrations. 
 
Publication bias 
Potential publication bias was explored using visual inspection of Begg’s funnel plot 
asymmetry, and Begg’s rank correlation and Egger’s weighted regression tests. Duval and 
Tweedie “trim and fill” method was used to adjust the analysis for the effects of publication bias 
[23].  
 
RESULTS 
Search results and trial flow 
The initial screening for potential relevance removed the articles whose titles and/or abstracts 
were obviously irrelevant. After assessment, 9 RCTS with 10 treatment arms achieved the 
inclusion criteria and were selected for the final meta-analysis [24-32]. 7 RCTs (7 treatment 
arms) determined plasma adiponectin concentrations and 5 RCTs with 6 treatment arms 
evaluated plasma leptin concentrations. A study flow chart is presented in Figure 1.  
In the selected studies, 248 participants were allocated to vitamin D supplementation and 236 
as controls. The number of participants in these trials ranged from 30 to 81. The studies included 
were published between 2012 and 2015, and were conducted in the USA (3 studies), Iran (3 
studies), Italy, Australia and Israel. All the studies used the oral route of administration. Six 
studies used multiple daily doses and 3 studies, a single bolus dose. The doses of vitamin D 
ranged from 400 to 4000 IU/day in multiple daily doses administration. Duration of 
supplementation with vitamin D ranged between 12 weeks and 12 months when daily doses were 
given. When single bolus dose was used the doses of vitamin D ranged between 50,000 IU/week 
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for 8 weeks to 300,000 IU administered once with 24 weeks follow-up. All trials were designed 
as parallel-group studies. Demographic and baseline parameters of the included studies are shown 
in Table 1. No adverse events related to the supplementation were reported. 
 
Risk of bias assessment 
We observed an unclear risk of bias regarding sequence generation, allocation concealment 
and blinding of outcome assessment in some of the studies, but studies were low-risk in terms of 
other sources of bias. The systematic assessment of bias in the included trials is presented in 
Table 2. 
 
Effect of vitamin D supplementation on plasma adiponectin concentrations 
Meta-analysis of data from 7 treatment arms did not suggest a significant alteration in plasma 
adiponectin concentrations following vitamin D supplementation (MD: 4.45%, 95% CI: -3.04, 
11.93, p=0.244; Q=2.18, I2=0%) (Figure 2A). The pooled effect size was robust and remained 
significant in the leave-one-out sensitivity analysis (Figure 2B). When the studies were 
categorized according to the treatment modality, there was no significant effect in either of the 
subsets administering vitamin D as a single bolus dose (MD: 3.18%, 95% CI: -11.32, 17.68, p = 
0.667; Q=0.76, I2=0%) or multiple daily dose (MD: 4.91%, 95% CI: -3.83, 13.64, p=0.271; 
Q=1.38, I2=0%) (Figure 3A). In meta-regression, changes in plasma adiponectin concentrations 
following vitamin D supplementation were found to be independent of treatment duration (slope: 
0.25; 95% CI: -0.69, 1.19; p=0.603), baseline serum 25(OH)D (slope: -1.09; 95% CI: -4.39, 2.20; 
p=0.515) and changes in serum 25(OH)D levels (slope: -0.02; 95% CI: -0.15, 0.12; p=0.780) 
(Figures 4A, 4B and 4C).  
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Effect of vitamin D supplementation on plasma leptin concentrations 
Meta-analysis of data from 6 treatment arms did not suggest a significant alteration in plasma 
leptin concentrations following vitamin D supplementation (MD: -4.51%, 95% CI: -25.13, 16.11, 
p=0.668; Q=6.41, I2=21.97%) (Figure 5A). Sensitivity analysis showed that this effect size is 
sensitive to one of the studies; removing of which resulted in a significant reduction in plasma 
leptin levels (MD: -12.81%, 95% CI: -24.33, -1.30, p=0.029; Q=1.50, I2=0%) (Figure 5B). When 
the studies were categorized according to the treatment modality, there was no significant effect 
in either of the subsets administering vitamin D as a single bolus dose (MD: 25.09%, 95% CI: -
52.15, 102.33, p=0.524; Q=0, I2=0%) or multiple daily dose (MD: -5.70%, 95% CI: -28.39, 
17.00, p=0.623; Q=5.55, I2=27.92%) (Figure 3B). In meta-regression, changes in plasma leptin 
concentrations following vitamin D supplementation were found to be independent of treatment 
duration (slope: -1.93; 95% CI: -4.08, 0.23; p=0.080) and baseline serum 25(OH) D (slope: 2.00; 
95% CI: -4.11, 8.10; p=0.522) (Figure 6A and 6B). However, changes in serum 25(OH)D were 
found to be significantly associated with changes in plasma leptin levels following vitamin D 
supplementation (slope: 1.05; 95% CI: 0.08, 2.02; p=0.033) (Figure 6C). 
 
Publication bias 
Visual inspection of funnel plots suggested asymmetry in the meta-analyses of vitamin D 
and adipokines that was addressed by imputing one (for adiponectin) and three (for leptin) 
potentially missing studies using “trim and fill” method. The corrected effect sizes were 
calculated to be 4.17 (95% CI: -3.28, 11.62) (for adiponectin) (Figure 7A) and -13.97 (95% CI: -
37.88, 9.93) (for leptin) (Figure 7B).  
The results of Egger’s linear regression did not show any sign of publication bias for the 
adiponectin (intercept = 0.67, standard error = 0.31; 95% CI = -0.14, 1.47, t = 2.13, df = 5, two-
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tailed p = 0.087) and leptin (intercept = 1.08, standard error = 0.54; 95% CI = -0.41, 2.56, t = 
2.01, df = 4, two-tailed p = 0.115) meta-analyses. Although Begg’s rank correlation test did not 
suggest any publication bias in the adiponectin meta-analysis (Kendall’s Tau with continuity 
correction = 0.57, z = 1.80, two-tailed p-value = 0.072), there was a significant publication bias 
detected in the leptin meta-analysis (Kendall’s Tau with continuity correction = 0.80, z = 2.25, 
two-tailed p-value = 0.024). 
 
DISCUSSION  
To our knowledge, the current systematic review and meta-analysis is the first to evaluate the 
current evidence from RCTs on the efficacy of supplementation with vitamin D on plasma 
adiponectin and leptin concentrations. The results of this meta-analysis of 9 RCTs did not 
indicate a significant effect of vitamin D supplementation on adiponectin and leptin levels. In 
meta-regression, changes in plasma adiponectin and leptin concentrations following vitamin D 
supplementation were found to be independent of treatment duration. The changes in serum 
25(OH)D were found to be significantly associated with changes in plasma leptin levels, but 
independent of plasma adiponectin concentrations following vitamin D supplementation.  
The preliminary results obtained in a prior meta-analysis on 6 RCTs suggested a potential 
increase of serum adiponectin after vitamin D supplementation [33]. Those results had indicated 
a significant dose-response relationship between vitamin D supplementation and adiponectin 
levels [33]. However, that meta-analysis collected data only from one database (PubMed), had 
very small number of participants, and the final results are still not available. In comparison, our 
meta-analysis is larger, used multiple datasets, and performed rigorous statistical analyses 
including sensitivity analyses and assessment of risk of bias.   
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The exact mechanisms, by which vitamin D may influence leptin expression and secretion, 
are still unclear. To address this question, Kong et al. tested in vivo and ex vivo the effect of 
vitamin D on leptin expression [34]. It has been noticed that serum leptin levels and adipose 
leptin mRNA transcript significantly increase after one-week treatment with vitamin D analog 
RO-27-5646 [34]. These data showed that 1,25(OH)2D stimulated the production of adipose 
leptin production in a vitamin D receptor-dependent manner, suggesting that vitamin D may 
modify the energy homeostasis via direct regulation of leptin expression [34]. In contrast, an in 
vitro study showed that the treatment of human adipose tissue cultures with 1.25(OH)2D3 for up 
to 96 h inhibited leptin secretion at 72-92 h, suggesting an indirect effect of vitamin D on leptin 
regulation [35]. Supplementation with vitamin D significantly elevated serum leptin 
concentrations in asymptomatic vitamin D-deficient subjects [36]. These results were in 
agreement with those published by Maggi et al. [28] and Ghavamzadeh et al. [31].  
It might be assumed that a low intake of vitamin D may be associated with low leptin 
concentrations, increased appetite and weight. Indeed, the mechanism by which vitamin D 
supplementation may increase the serum leptin levels and reduce weight seems to be related to 
the bidirectional adipoinsular axis involving appetite suppression, regulation of insulin secretion 
and increased glucose uptake [37, 38]. Besides that, a growing number of epidemiological studies 
have shown an inverse correlation between BMI and serum levels of 25(OH)D in humans. In the 
same manner, Vilarrasa et al. also obtained an inverse correlation between BMI, body fat, waist, 
hip circumference and serum levels of 25(OH)D and leptin in a healthy population [39]. 
However, no significant associations were observed between serum levels of 25(OH)D and other 
adipokines measured such as resistin, interleukin-18 and adiponectin [39]. Vitamin D may also 
be involved in the regulation of adiponectin levels through modification of insulin sensitivity. 
Baziar et al. [24] reported significantly increased levels of 25(OH)D and decreased levels of 
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fasting serum glucose, insulin and insulin resistance (p = 0.04, 0.02 and 0.007, respectively) after 
vitamin D supplementation. However, supplementation with vitamin D in a therapeutic dose had 
no effect on serum adiponectin concentrations. It appears likely there the measurement of total 
adiponectin level might be a significant limitation for this study. It should be noted that two 
forms of circulating adiponectin were measured – low-molecular weight (LMW) and high-
molecular weight (HMW) adiponectin. The second one is the active form and the ratio of HMW 
to total adiponectin is considered more accurate for the assessment of the insulin resistance and 
adiponectin association [40]. Similar results were obtained by Breslavsky et al. (1000 IU/day 
vitamin D for 12 months) [26] and Patel et al. (400 IU and 1200 IU/day for 4 months) [41]. 
However, in the first study, supplementation with vitamin D did not normalized serum 
adiponectin levels, while the second study had a small sample size and a control group was 
absent.  
The positive association between vitamin D supplementation and serum adiponectin 
concentrations observed in cross-sectional studies may be caused by increased expression of 
adiponectin gene or changes of activity of the renin-angiotensin-aldosterone system [42]. 
Activated vitamin D is a negative inhibitor of the renin-angiotensin-aldosterone system. It has 
been shown that increased activity of the renin-angiotensin-aldosterone system is associated with 
increased angiotensin production, leading to decreased serum adiponectin concentrations. 
Therefore, vitamin D may increase serum adiponectin concentrations through decreasing the 
angiotensin production [43]. Another possible mechanism explaining the association between 
vitamin D and adiponectin is the regulation of the adiponectin gene expression through 
1,25(OH)2D3, the active form of vitamin D, which has receptors located in preadipocytes [44]. 
Furthermore, 1,25(OH)2D3 might play an important role in regulation of tumor necrosis factor-α 
production which is involved in adiponectin synthesis [45-48].  
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The present meta-analysis has some limitations. First, the qualified RCTs generally had very 
modest populations (none recruited more than 100 patients) and limited follow-up. Second, the 
studies involved were heterogeneous concerning the population similarities (age), the duration of 
the study as well as type and dose of vitamin D. Third, the relationship between all adipokines 
with vitamin D could not be performed because of the relatively small number of available 
studies. There is also no information in the included studies on the seeasonal’s vitamin D 
changes.  
In conclusion, this meta-analysis did not find a significant effect of supplementation and 
treatment with vitamin D on plasma adipokine concentrations. However, recent studies suggest 
that adipokines and adipose tissue may be a direct target for vitamin D. The expression of both 
the vitamin D receptor and 25-hydroxyvitamin D 1α-hydroxylase (CYP27B1) genes has been 
demonstrated in murine and human adipocytes. Some recent studies have also shown that vitamin 
D metabolites might influence an increased adipokines production. Since adipokines are 
associated with a better glycemic control and other metabolic indicators, a possible explanation 
why vitamin D supplementation may have a significant impact on the adipokine levels is needed, 
especially in patients with type 2 DM, metabolic syndrome or obesity. 
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Table 1. Demographic characteristics and baseline parameters of the studies selected for analysis.  
Study  Baziar et 
al.[24] 
Belenchia 
et al.[25] 
Breslavsky 
et al. [26] 
Gagnon et al. 
[27] 
Maggi et 
al.[28] 
Neyestani et 
al.[29] 
Shah et al. [30] Ghavamzad
eh et al. [31] 
Chai et al. 
[32] 
Year  2014 2013 2013 2014 2013 2012 2015 2014 2012 
Location  Iran USA Israel Australia Italy Iran USA Iran USA 
Design  Randomize
d double-
blind  
placebo-
controlled 
parallel 
group trial 
Randomize
d double-
blind 
placebo-
controlled 
parallel 
group trial 
Randomized 
double-blind 
placebo-
controlled 
parallel 
group trial 
Randomized 
double-blind 
placebo-
controlled 
parallel group 
trial 
Randomized 
double-blind 
placebo-
controlled 
parallel group 
trial 
Randomized 
double-blind 
controlled 
parallel 
group trial 
Randomized 
double-blind 
placebo-
controlled 
parallel group 
trial 
Randomized 
double-blind 
placebo-
controlled 
parallel 
group trial 
Randomized 
double-blind, 
placebo-
controlled 
parallel group 
trial 
Trial duration  2 months  6 months 12 months 6 months 6 months 3 months 6 months 3.5 months 6 months 
Inclusion 
criteria 
 Type 2 
diabetic 
patients 
aged 31-65, 
BMI > 25 
and < 30 
kg/m2, 
serum 
25(OH)D 
10-30 
ng/mL, 
glycated 
hemoglobin 
(HbA1c) < 
8%, no 
alcohol 
consumptio
n and 
smoking, 
insulin 
therapy, 
consuming 
thiazolidine
diones, 
pregnancy 
or 
Obese 
adolescent 
patients  
aged 
between 9 
and 19 yrs 
and at least 
at the 85th 
percentile 
for BMI 
Patients with 
type 2 
diabetes 
mellitus 
recruited 
from the 
hypertension 
outpatient 
clinic 
Vitamin D-
deficient men 
and women 
aged ≥18 yrs 
and at risk of 
type 2 diabetes 
(BMI between 
25 and 40 
kg/m2, a serum 
25(OH)D 
concentration 
≤50 nmol/L 
[<20.1 ng/mL] 
and fasting 
plasma glucose 
6.1–6.9 
mmol/L and/or 
2-h plasma 
glucose post 75 
g glucose load 
7.8–11.0 
mmol/L [140-
200 mg/dL]) 
Patients who 
were 60 yrs or 
older with 
type 2 
diabetes 
mellitus and 
diabetic foot 
complications 
Type 2 
diabetes 
subjects 
(fasting 
blood 
glucose 
concentratio
n >126 
mg/dl; not 
taking 
steroidal 
anti-
inflammator
y or 
anticoagulan
t 
medications; 
not taking 
dietary 
supplements 
including 
calcium, 
vitamin D, 
or omega-3 
within the 
past 3 
Overweight and 
obese 
adolescents (ages 
≥11and <18 yrs, 
BMI of ≥85th 
percentile for age 
and gender, and 
serum 25(OH)D 
concentration 
between 10 and 
60 ng/mL) 
Type 2 
diabetic 
patients on 
glucose 
lowering 
agents, – but 
not insulin-  
not suffering 
from other 
illnesses 
(such as 
cardiovascula
r diseases, 
renal failure, 
and/or 
inflammatory 
diseases) non 
supplemented  
with vitamin 
D and/or Ca 
Adults aged 30 
to 75 yrs, in 
general health,  
with a history of 
at least 
one pathology-
confirmed 
adenomatous 
colorectal polyp 
within the past 
36 months, no 
contraindication
s to calcium or 
vitamin D 
supplementation 
or rectal biopsy 
procedures and 
no medical 
conditions, 
habits, or 
medication 
usage that 
would otherwise 
interfere with 
the study 
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menopause, 
consuming 
vitamin D-
interfering 
drugs 
(corticoster
oids, 
antiepileptic
s and 
contraceptiv
es) and also 
calcium and 
vitamin D 
supplement
ation in last 
six months, 
no history 
of 
myocardial 
infarction, 
angina 
pectoris and 
stroke in 
last year or 
suffering 
from 
cardiovascu
lar, liver, 
kidney, 
thyroid 
gland 
diseases and 
chronic 
inflammatio
n. 
months 
before the 
intervention; 
not receiving 
medications 
that could 
potentially 
influence 
vitamin D 
metabolism 
or insulin; 
not having 
any other 
clinical 
disease that 
could 
influence 
vitamin D 
metabolism) 
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Type and dose 
of vitamin D 
 50000 IU 
vitamin D3 
soft gelatin 
spherical 
pearls 
single 
dose/week 
2x2000 IU 
vitamin D3 
pills/day 
1000 IU 
vitamin D3 
capsules/day 
Combination 
2000 IU 
vitamin D3 
capsules+1200 
mg Ca/day for 
the first 2 
months; 
Combination 
4000 IU 
vitamin D3  
capsules+1200 
mg Ca/day for 
the next 2 
months; 
Combination 
6000 IU 
vitamin D3  
capsules+1200 
mg Ca/day for 
the last 2 
months 
A single dose 
of 300,000 IU 
vitamin D3 
Vitamin D-
fortified 
doogh 
(Persian 
yogurt 
drink), 
containing 
500 IU 
vitamin D3 
and 150 mg 
calcium /250 
ml, 2 times 
daily 
150,000 IU 
vitamin D2 
capsule at 
baseline and 
another 150,000 
IU vitamin D2 
capsule after 12 
weeks 
Vitamin D3 
(cholecalcifer
ol) 400 IU 
/ml (10 
mcg/ml) plus 
thin 
vegetable oil 
(purified 
component of 
coconut and 
palm oil) 
800 IU vitamin 
D3 
 
800 IU vitamin 
D3 +2 g Ca 
elemental 
Participants VitD 41 18 24 35 14 30 14 26 23 
23 
Contro
l  
40 17 23 45 16 30 17 25 23 
Age (years) VitD 50.34±6.7
1 
 
14.6± 2.3 66.8±9.2 53.8±11.9 69* 51.5±5.4 15.1±0.4** 52.26±2.09** 60.2±8.1 
62.1±7.5 
Contro
l  
52.75±6.34 13.9± 2.4 65.8±9.7 55.3±11.1 50.8±6.7 13.6±0.4** 49.28±2.00** 58.5±8.2 
Male (%) VitD 68.29 52.0 45.83 29.0 64.28 NA 40.0 41.18 70.0 
70.0 
Contro
l 
65.0 48.0 47.83 33.0 87.5 NA 30.0 70.0 
BMI (kg/m2) VitD 27.33±1.64 39.5±5.1 27.9±5.2 31.1±5.7 29* 29.2±4.4 36.0±1.6** 28.9±0.86 28.9±5.6 
31.6±6.0 
Contro
l 
27.25±1.35 38.9±6.7 30.6±5.1 31.9±6.2 29.9±4.7 31.0±1.1** 27.9±0.93 30.6±7.2 
Adiponectin, 
(ng/mL) 
VitD 3480±1570   5860±200 10.37±6.57 6070±3613† 14,045.4±12,6
98.9 
105.5±68.7 4.8∙10-3 (3.4∙10-3-
6.7∙10-3) ‡ 
NA NA 
NA 
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Contro
l 
4040±3980 5880±210 15.81±11.31 6424±4408† 12,205±8,286.
7 
105.3±83.1 7.2∙10-3(3.6∙10-3-
8.8∙10-3) ‡ 
NA NA 
Leptin 
(ng/mL) 
VitD NA 43.5± 1.8 27.88±27.97 NA 18.83±16.66 NA NA 11.96± 2.18** 14.9±4.4** 
26.3±4.5** 
Contro
l 
NA 43.5±1.9 30.54±28.96 NA 12.36±14.03 NA NA 11.20± 1.96** 17.2±4.5** 
Serum 
25(OH)D 
ng/ml 
VitD 14.33±5.85 19.2±  6.3 11.8±10.9 18.8±5.2 11.2±4.36 17.6±11.6 19.6±1.4** 21.46±4.65** 19.4±1.9** 
 
18.8±1.9** 
Contro
l  
15.50 ±5.55 19.6±7.9 11.7±6.5 17.2±5.2 13.6±6.91 
 
16.8±18.0 25.8±2.6** 22.16±5.32** 18.8±1.9** 
SBP (mmHg) VitD NA NA 154.2±21.5 120.8±14.0 NA NA NA NA NA 
Contro
l  
NA NA 151.8±18.0 126.8±12.1 NA NA NA NA NA 
DBP (mmHg) VitD NA NA 76.2±8.8 73.1±10.0 NA NA NA NA NA 
Contro
l 
NA NA 72.2±10.8 76.8±8.9 NA NA NA NA NA 
Values are expressed as mean±SD; *only mean; **values are expressed as mean ± SEM; † - logarithmically-transformed variables; ‡ - median (interquartile range) 
Abbreviations: SD: standard deviation; SEM: standard error of the mean; BMI: body mass index; NA: not available; 25 (OH) D: 25-hydroxyvitamin D; SBP: systolic blood 
pressure, DBP: diastolic blood pressure.  
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Table 2. Assessment of risk of bias in the included studies using Cochrane criteria 
 
Study Ref SEQUENCE 
GENERATION 
ALLOCATION 
CONCEALMENT 
BLINDING OF 
PARTICIPANTS 
AND PERSONNEL 
BLINDING OF 
OUTCOME 
ASSESSMENT 
INCOMPLETE 
OUTCOME 
DATA 
SELECTIVE 
OUTCOME 
REPORTING 
OTHER 
POTENTIAL 
THREATS TO 
VALIDITY 
Baziar et al. 
2014 
[24] U U L U L L L 
Belenchia et al. 
2013 
[25] L L L U L L L 
Breslavsky et 
al. 2013 
[26] U U L L L L L 
Gagnon et al. 
2014 
[27] L L L U L L L 
Maggi et al. 
2013 
[28] L L L U L L L 
Neyestani et al. 
2012 
[29] U U L U L L L 
Shah et al. 2015 [30] L L L U L L L 
Ghavamzadeh 
et al. 2014 
[31] U U L U L L L 
Chai et al. 2012 [32] U U L L L L L 
 
L: low risk of bias; H: high risk of bias; U: unclear risk of bias. 
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FIGURE LEGENDS:  
Figure 1. Flow chart of the number of studies identiﬁed and included into the meta-analysis.   
Figure 2. Forest plot displaying mean difference and 95% confidence intervals for the impact of 
vitamin D supplementation on plasma adiponectin concentrations (Figure 2A). Lower plot shows 
leave-one-out sensitivity analysis (Figure 2B). 
Figure 3. Forest plot displaying mean difference and 95% confidence intervals for the impact of 
single bolus dosing and multiple daily dosing of vitamin D on plasma adiponectin (Figure 3A) 
and leptin (Figure 3B) concentrations. 
Figure 4. Meta-regression plots of the association between mean changes in plasma adiponectin 
concentrations with duration of supplementation (Figure 4A), baseline serum 25(OH)D (Figure 
4B) and changes in serum 25(OH)D concentrations (Figure 4C). 
Figure 5. Forest plot displaying mean difference and 95% confidence intervals for the impact of 
vitamin D supplementation on plasma leptin concentrations (Figure 5A). Lower plot shows 
leave-one-out sensitivity analysis (Figure 5B). 
Figure 6. Meta-regression plots of the association between mean changes in plasma leptin 
concentrations with duration of supplementation (Figure 6A), baseline serum 25(OH)D (Figure 
6B), and changes in serum 25(OH)D concentrations (Figure 6C),. 
Figure 7. Funnel plot displaying publication bias in the studies reporting the impact of vitamin D 
supplementation on plasma adiponectin (Figure 7A) and leptin (Figure 7B) concentrations. 
 
 
 
 
